shopping cart
nothing in cart
 
2012 resource catalogue
browse by subject
textbooks
new releases
best sellers
sale books
browse by author
browse by publisher
home
about us
upcoming events
May 23rd - Afternoon Discussion Series - "The Delicate Dance of Helping" [CAST Canada]
May 24th - Therapeutic Presence: Strengthening Your Foundation for Effective Therapy [Leading Edge Seminars, Inc]
May 25th - TICP Spring 2013 Conference - Meaning, Mortality and Music: Existential and Evolutionary Perspectives [TICP-Toronto Institute for Contemporary Psychoanalysis]
May 27th - The Joy of Gender: Counselling Transgender Clients and Their Families [Leading Edge Seminars, Inc]
May 28th - Dialectical Behaviour Therapy: A Workshop for Direct Service Workers [Hincks-Dellcrest Institute]
schools agencies and other institutional orders (click here)
Pharmacotherapy of Child and Adolescent Psychiatric Disorders, Third Edition
Rosenberg David R. and Samuel Gershon (Eds)
Wiley / Hardcover / 2012-02-01 / 0470973765
Psychopharmacology / Child Psychiatry
price: $110.00
474 pages
In Stock (Ships within one business day)

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.Third edition of the first ever book published on pediatric psychopharmacology from renowned editors.Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior.Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD.Features many tables, figures and pictorials, making it highly accessible and reader friendly.

About the Editors:

David Rosenberg MD, Miriam L. Hamburger Endowed Chair of Child Psychiatry and Professor & Chief of Child Psychiatry and Psychology at Wayne State University and the Children's Hospital of Michigan, Detroit, MI , USA

Samuel Gershon MD, Emeritus Professor of Psychiatry, University of Pittsburgh, PA, USA

Caversham Booksellers
98 Harbord St, Toronto, ON M5S 1G6 Canada
(click for map and directions)
All prices in $cdn
Copyright 2004

Phone toll-free (800) 361-6120
Tel (416) 944-0962 | Fax (416) 944-0963
E-mail info@cavershambooksellers.com
Store hours : 9-6 M-W / 9-7 Th-F / 10-6 Sat / 12-5 Sun EST

search
other lists
Child Psychiatry
Psychopharmacology